The firm is one of the leading manufacturers of APIs for anti-retroviral (ARV), Hepatitis C, and Oncology
Total revenue grew 16.7% to Rs 478.4 cr
On the NSE, the stock listed at Rs 489.90 and gained as much as Rs 498
The IPO, which opened to public subscription on December 6-8, was subscribed 4.54 times at a price band of Rs 426-428 per share
The Rs 1,332-cr IPO received bids for over 9.87 crore shares as against the total issue size of over 2.19 crore scrips
The firm proposes to use the net proceeds from the fresh issue towards pre-payment of term loans